整理 | GLP1减重宝典内容团队 2025年9月4日，礼来在ClinicalTrials.gov登记了小分子GLP-1受体激动剂Orforglipron用于肥胖合并膝骨关节炎的Ⅲ期研究ATTAIN-OA PAIN。 | Brief Summary | Study Start (Estimated) 0 | | --- | --- | | The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and | 2025-09 | | J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people | | | with obesity or overweight who have osteoarthritis (OA) of the knee with pain. | Primary Completion (Estimated) ● | | Participation in the study will last about ...